Skip to content

Observational Study of the LMA Protector

ADEPT 1 - Observational Study of the LMA Protector

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03664700
Acronym
ADEPT1
Enrollment
112
Registered
2018-09-10
Start date
2019-11-05
Completion date
2021-08-01
Last updated
2025-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Airway Complication of Anesthesia

Keywords

Supraglottic airway device, LMA Protector

Brief summary

The investigators want to investigate the user friendliness, and performance of the LMA Protector. The principal research question is to assess the overall performance of the LMA Protector. The investigators are merely making observations related to use of the device during clinical practice.

Detailed description

There is a lack of research data on regarding the use of the LMA Protector. There is no regulatory requirement to collect or publish patient data on any device, either before CE marking or after. These devices are freely purchased and used. There is, however, a professional duty to know that a device conforms to established norms for use. These norms are not official standards but rather, reference data against which a device can be clinically judged. Therefore, a device that is easy to insert but has a low 'leak pressure' (see above) is different from one that is more difficult to insert but as a high leak pressure. It is not that one is 'better' than the other, but rather that the data help create a 'usability profile' of the device which can be useful when making a clinical selection for the device. Preoperative assessment: During the preoperative visit, patient information leaflet will be given to the patients meeting the eligibility criteria. Wherever possible, suitable patients will be identified in the preoperative assessment clinic and the information leaflet given. The patients will be given adequate time to read this information and any queries will be answered before being asked to sign a consent form. A detailed airway assessment will be performed by one of the investigators and documented on the study proforma. Induction of anaesthesia: On arrival in the anaesthetic room patients will be monitored with pulse oximetry, electrocardiography and invasive or non-invasive blood pressure measurements. After intravenous access is secured and the pre-surgical checklist completed, all patients will be pre-oxygenated using a facemask to achieve end tidal oxygen concentration of at least 80%. A 'sniffing' position of the head and neck and a 20 degree head-up bed tilt will be used for pre-oxygenation. General anaesthesia will be induced intravenously. After induction of anaesthesia, facemask ventilation will be commenced and anaesthesia maintained with an inhalational anaesthetic agent in oxygen or with total intravenous anaesthesia. The volatile agent's (anesthetic gases) concentration of 1 MAC adjusted for the patient's age will be achieved and maintained. This is normal process of anaesthesia applicable for all patients irrespective of participation in the study. Supraglottic airway device (SAD) insertion: Once deep plane of anaesthesia is confirmed, with the absence of movement to jaw thrust stimulation the SAD (LMA protector) will be inserted. The size of the device will be based on the manufacturer's recommendations for the body weight. The breathing system will be connected to the device. Ventilation of the lungs will be then confirmed by observing adequate bilateral chest inflation and square end-tidal capnogram wave with positive pressure ventilation. Adequate ventilation will be recorded if three tests are passed: 1) adequate chest movement, 2) an expired tidal volume of at least 7 ml/kg and 3) stable oxygenation. Time would continue until LMA® ProtectorTM inserted successfully. If it is not possible to insert the device or ventilate through it, two more attempts at placement of the device will be allowed. If placement has failed after two further attempts, the study will be abandoned and the other device will be used. If this fails on first attempt a different LMA or tracheal tube will be used as appropriate. Maintenance of anaesthesia and recovery The main interventions refer to the insertion of the airway device into the patient to obtain a airway and allow the conduct of the anaesthetic and therefore the surgery. However, if there are problems with the device and the airway obtained is suboptimal then the below interventions are allowed (which will be noted in the data collection form): 1. Neck extension - move patient's neck upward 2. Neck flexion - move patient's neck downward 3. Chin lift - manoeuvre to open the airway 4. Jaw thrust - manoeuvre to open the airway 5. Reposition of the device At the end of operation, anaesthetic agents will be discontinued while the device is left in place. The device will be removed after the patient has regained consciousness, and has responded to verbal command to open the mouth. Any complications that occur during the use of the device will be recorded. Postoperative assessment Postoperatively in recovery or on the ward, the investigators will visit each patient and determine whether the following airway complications are present after surgery: sore throat (constant pain, independent of swallowing), dysphagia (difficulty in, or pain provoked by, swallowing), sore jaw, dysphonia (difficulty in, or pain on, speaking), numbness of the tongue or the oropharynx, ear pain, neck or mouth ache, hearing changes. Each complication will be graded as none, mild, moderate or severe. The same questions will be asked 24-48 hours later. First visit During the first visit by the anaesthetist to the participant, at the anaesthetist's earliest opportunity, either in the recovery area or on the ward, the participants will be asked about the following complications, which will be graded as none, mild, moderate or severe. 1. Vomiting 2. Lip or tongue swelling 3. Hearing changes 4. Ear pain 5. Sore throat 6. Pain on swallowing 7. Jaw pain 8. Neck or mouth ache 9. Pain on speaking 10. Numbness of the tongue Second visit (or telephone consultation) During the second visit 24-48 hours post-operatively on the ward or via telephone the participants will be asked about the following complications, which will be graded as none, mild, moderate or severe. 1. Vomiting 2. Lip or tongue swelling 3. Hearing changes 4. Ear pain 5. Sore throat 6. Pain on swallowing 7. Jaw pain 8. Neck or mouth ache 9. Pain on speaking 10. Numbness of the tongue

Interventions

The LMA Protector will be inserted when a supraglottic device is needed

Sponsors

Royal United Hospital Bath NHS Trust
CollaboratorOTHER
Royal Berkshire NHS Foundation Trust
CollaboratorOTHER_GOV
Northampton General Hospital NHS Trust
CollaboratorOTHER
University Hospital of Wales
CollaboratorOTHER
Oxford University Hospitals NHS Trust
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult participants who are having a general anaesthetic. * Participant is willing and able to give informed consent for participation in the study. * Male or Female, aged 18 years or above. * ASA 1 - 3 category patients * Elective operations * Urgent operations * Patients suitable for an SAD based on patient and operation factors.

Exclusion criteria

The participant may not enter the study if ANY of the following apply: * Refusal of consent * Age less than 18 years * Require intubation for the operation * Risk of regurgitation * ASA 4 and above * Mouth opening less than 2.5cm Require awake intubation

Design outcomes

Primary

MeasureTime frameDescription
First go Insertion Success RateDay 1Whether insertion during first go was successful or not
First go Successful Ventilation RateDay 1Whether ventilation during first go was successful or not
Number of Participants With Complication Free InsertionsDay 1Number of participants with complication free insertions divided by total number of participants

Secondary

MeasureTime frameDescription
Number of Participants With Visible Chest MovementDay 1The success of ventilation will depend on whether there was visible chest movement
Number of Participants With Adequate Tidal Volume at Attempt of VentilationDay 1The success of ventilation will depend on whether there was tidal volume \> 7ml/kg
Time to First Square Capnography WaveformDay 1Record time in seconds of time to first capnography trace
Number of Participants With Square Capnography TraceDay 1The success of ventilation will depend on whether there was square capnography trace
Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalDay 1Collect number of pre-defined complications of device usage
Number of Participants With Stable Oxygen SaturationsDay 1The success of ventilation will depend on whether there was stable SpO2
Lowest Oxygen Saturation LevelDay 1Record of lowest oxygen saturation reading across all participants
Interventions Needed to Ensure Airway PatencyDay 1Collect number of predefined interventions needed to keep airway patent

Countries

United Kingdom

Participant flow

Participants by arm

ArmCount
LMA Protector
The LMA Protector will be used LMA Protector: The LMA Protector will be inserted when a supraglottic device is needed
111
Total111

Baseline characteristics

CharacteristicLMA Protector
Age, Continuous68 years
Race and Ethnicity Not Collected— Participants
Region of Enrollment
Ireland
61 Participants
Region of Enrollment
United Kingdom
50 Participants
Sex: Female, Male
Female
58 Participants
Sex: Female, Male
Male
53 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 111
other
Total, other adverse events
39 / 111
serious
Total, serious adverse events
1 / 111

Outcome results

Primary

First go Insertion Success Rate

Whether insertion during first go was successful or not

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
LMA ProtectorFirst go Insertion Success Rate100 Participants
Primary

First go Successful Ventilation Rate

Whether ventilation during first go was successful or not

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
LMA ProtectorFirst go Successful Ventilation Rate110 Participants
Primary

Number of Participants With Complication Free Insertions

Number of participants with complication free insertions divided by total number of participants

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
LMA ProtectorNumber of Participants With Complication Free Insertions72 Participants
Secondary

Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal

Collect number of pre-defined complications of device usage. Secondary complication where asked about on Day 2 to ensure patients had recovered from the effects of the anaesthetic and are able to report any complications.

Time frame: Day 2

Population: Further breakdown of when complications occurred and the pre-defined complications of device usage are presented for the number of participants who experienced complications.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalNumber who experienced complications13 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalVomiting1 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalSore throat10 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalPain on swallowing1 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalNeck or mouth ache1 Participants
Secondary

Complications Occurrence During Insertion of Device, During Anaesthesia, and on Device Removal

Collect number of pre-defined complications of device usage

Time frame: Day 1

Population: Further breakdown of when complications occurred and the pre-defined complications of device usage are presented for the number of participants who experienced complications.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalNumber who experienced complications39 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalNumber who experienced complications immediately following device insertion6 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalNumber who experienced complications during maintenance of anaesthesia1 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalNumber who experienced complications upon extubation32 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalNumber who experienced mucosal injury19 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalNumber who experienced mild post-operative sore throat37 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalNumber who experienced mild pain on swallowing12 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalNumber who experienced mild post-operative dysphonia7 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalNumber who experienced mild mouth pain3 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalNumber who experienced mild jaw pain3 Participants
LMA ProtectorComplications Occurrence During Insertion of Device, During Anaesthesia, and on Device RemovalNumber who experienced mild numbness of tongue1 Participants
Secondary

Interventions Needed to Ensure Airway Patency

Collect number of predefined interventions needed to keep airway patent

Time frame: Day 1

Population: The number analysed in one or more rows relates to the number of participants for whom 1 or more airway manipulations was required.

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
LMA ProtectorInterventions Needed to Ensure Airway Patency1 or more airway manipulation required67 Participants
LMA ProtectorInterventions Needed to Ensure Airway PatencyManipulation: Jaw thrust50 Participants
LMA ProtectorInterventions Needed to Ensure Airway PatencyManipulation: Neck extension45 Participants
LMA ProtectorInterventions Needed to Ensure Airway PatencyManipulation: Chin lift4 Participants
LMA ProtectorInterventions Needed to Ensure Airway PatencyManipulation: Reposition device3 Participants
Secondary

Lowest Oxygen Saturation Level

Record of lowest oxygen saturation reading across all participants

Time frame: Day 1

ArmMeasureValue (NUMBER)
LMA ProtectorLowest Oxygen Saturation Level91 Percent of oxygen saturation
Secondary

Number of Participants With Adequate Tidal Volume at Attempt of Ventilation

The success of ventilation will depend on whether there was tidal volume \> 7ml/kg

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
LMA ProtectorNumber of Participants With Adequate Tidal Volume at Attempt of Ventilation110 Participants
Secondary

Number of Participants With Square Capnography Trace

The success of ventilation will depend on whether there was square capnography trace

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
LMA ProtectorNumber of Participants With Square Capnography Trace110 Participants
Secondary

Number of Participants With Stable Oxygen Saturations

The success of ventilation will depend on whether there was stable SpO2

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
LMA ProtectorNumber of Participants With Stable Oxygen Saturations110 Participants
Secondary

Number of Participants With Visible Chest Movement

The success of ventilation will depend on whether there was visible chest movement

Time frame: Day 1

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
LMA ProtectorNumber of Participants With Visible Chest Movement110 Participants
Secondary

Time to First Square Capnography Waveform

Record time in seconds of time to first capnography trace

Time frame: Day 1

ArmMeasureValue (MEDIAN)
LMA ProtectorTime to First Square Capnography Waveform31 Seconds

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026